文献速递膀胱癌与上尿路尿路上皮癌

生化验证的诊断后吸烟与非肌层浸润性膀胱癌复发风险的关联

Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk.
PubMed 文献 · J Urol · 2022-01-27

前瞻性研究纳入354例有吸烟史的非肌层浸润性膀胱癌患者,2015至2018年接受诊疗,随访期间至少采集2份生物标本检测可替宁以判定诊断后吸烟暴露。中位随访3.6年,22%患者检出诊断后吸烟暴露,38.7%(137例)复发;多变量模型中诊断后吸烟暴露与复发风险无关联(HR 0.73,95%CI 0.45-1.20)。

要点

  • 354例有吸烟史的非肌层浸润性膀胱癌患者中,22%检出诊断后吸烟暴露。
  • 随访期间38.7%(137例)患者出现复发,中位随访3.6年。
  • 多变量模型中诊断后吸烟暴露与复发风险无关联(HR 0.73,95%CI 0.45-1.20)。

核心结论

  • 在主要为高危非肌层浸润性膀胱癌的患者队列中,诊断后吸烟暴露与非肌层浸润性膀胱癌复发无关联。
  • 作者指出戒烟支持仍是癌症照护的关键组成部分,因为戒烟的获益远不止于非肌层浸润性膀胱癌复发。

研究设计与样本

  • 前瞻性研究,纳入354例有吸烟史、2015至2018年间接受诊疗的非肌层浸润性膀胱癌患者。
  • 患者在随访期间至少提供2份生物标本,检测可替宁以判定诊断后吸烟暴露(是/否)。
  • 主要终点为研究开始日期后至首次复发的时间,采用多变量Cox比例风险模型分析,校正人口学、临床病理变量、自诊断时间和包年。

主要发现

  • 患者以白人、男性为主,中位年龄68岁。
  • 多数患者为Ta期病变(62%),肿瘤高级别者占68%。
  • 63%的队列接受了膀胱内卡介苗治疗。
  • 自研究开始中位随访3.6年,22%患者检出诊断后吸烟暴露,38.7%(137例)患者在随访期间复发。
  • 多变量模型中仅卡介苗治疗和既往复发率与复发显著相关;诊断后吸烟暴露与复发风险无关联(HR 0.73,95%CI 0.45-1.20)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to determine the association between biochemically verified post-diagnosis smoking exposure and nonmuscle-invasive bladder cancer (NMIBC) recurrence risk. MATERIALS AND METHODS: We conducted a prospective study of 354 NMIBC patients with a smoking history undergoing care between 2015 and 2018. Patients contributed at least 2 biospecimens during followup which were tested for cotinine to determine biochemically verified post-diagnosis smoking exposure (yes/no). Our primary endpoint was time to first recurrence after study start date. We examined whether post-diagnosis smoking exposure was associated with recurrence risk in multivariable Cox proportional hazards models that accounted for demographics, clinicopathological variables, time since diagnosis and pack-years. RESULTS: Patients were predominantly White, male and had a median age of 68 years. Most patients had Ta disease (62%) and tumors of high grade (68%). Intravesical bacillus Calmette-Guérin was given to 63% of the cohort. Patients were followed for a median of 3.6 years since study start. Post-diagnosis smoking exposure was detected in 22% of patients, and 38.7% (137) of patients experienced a recurrence during followup. In multivariable models, only bacillus Calmette-Guérin treatment and prior recurrence rate were significantly associated with recurrence. There was no association between post-diagnosis smoking exposure and recurrence risk (HR: 0.73, 95% CI: 0.45-1.20). CONCLUSIONS: In a cohort of patients with predominantly high risk NMIBC, post-diagnosis smoking exposure was not associated with NMIBC recurrence. However, smoking cessation support remains a critical component of cancer care given that the benefits of quitting extend far beyond NMIBC recurrence.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Furberg H, Petruzella S, Whiting K, et al. Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk. J Urol. 2022. PMID: 35084998. doi:10.1097/JU.0000000000002449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。